Get started

Biotechnology

$ONTX Closing of $28.75 Million Public Offering of Common StockOnconova Therapeutics to Present Corporate Update at the 2021 BIO CEO & Investor Digital Conference-February 16-18, 2021 finance.yahoo.com Onconova Therapeutics, Inc. Announces Closing of $28.75 Million Public Offering of Common Stock Including Full Exercise of the Over-Allotment Option. A total of 28,750,000 shares of its common stock were sold, including 3,750,000 shares of common stock following the exercise by the underwriters of their over-allotment option, at a public offering price of $1.00 per share. finance.yahoo.com
O
by AlenCiken
$NVCN Regains Compliance with Nasdaq Minimum Bid Price RuleNeovasc Regains Compliance with Nasdaq Minimum Bid Price Rule Currently, the Company is still not in compliance with the minimum market value requirement set forth in Nasdaq Rules for continued listing on the Nasdaq. Nasdaq Listing Rule 5550(b)(2) requires companies to maintain a minimum market value of US$35 million; the Company has until June 8, 2021 to regain such compliance. The Company is also listed on the Toronto Stock Exchange and regaining compliance on the Nasdaq does not affect the Company’s compliance status with such listing. finance.yahoo.com
N
by AlenCiken
Topline data from the open-label, Phase 1b clinical trialDiffusion Pharmaceuticals Increases Previously Announced Bought Deal Offering of Common Stock to $30 Million, due to demand announced today that, due to demand, the underwriter has agreed to increase the size of the previously announced public offering and purchase on a firm commitment basis 29,268,294 shares of common stock of the Company at a price to the public of $1.025 per share, less underwriting discounts and commissions. finance.yahoo.com Diffusion Pharmaceuticals Completes Phase 1b Study of TSC in Hospitalized COVID-19 Patients No Dose Limiting Toxicities or Serious Adverse Events Observed in Dosing Regimen Previously Untested in Clinical Trial Setting. completion and topline data from the open-label, Phase 1b clinical trial of its novel. finance.yahoo.com
D
by AlenCiken
Jefferies upgraded $PRTA to buy from neutral-100% upside1. Jefferies upgraded the stock to buy from neutral expecting a 100% upside to the stock. Citing the ‘positive momentum and pipeline execution’ and rising investor attention, the analyst Michael Yee ups the price target to $30 from $15, nearly double its previous close. Prothena’s pipeline has significantly expanded and improved. The company’s early-stage candidates for Alzheimer’s disease ‘should start to garner more attention,’ Yee argues, projecting the three mid-to-late-stage assets to yield ‘a significant upside.’ Add more than $300M in cash and the partnerships with Bristol Myers and Roche, the stock ‘is primed to move up 100% towards $30+,’ concluded the analyst. Out of Prothena's two candidates, PRX012 and multi-immunogen vaccine, targeting the Alzheimer’s disease, the former is on track for an IND filing in Q1 2022, the company disclosed in the recent R & D update. ------------------------------------------------------------------------------------------------------------------------------------------------- 2. BTIG Research upgraded $PRTA from neutral to buy with price target $29. seekingalpha.com
NASDAQ:PRTA
by AlenCiken
2
$ARTL surged 92% on buy rating from Ladenburg analystArtelo Biosciences surged 92% on buy initiation from Ladenburg Shares of $ARTL Artelo Biosciences surged on friday after Ladenburg analyst Michael Higgins initiated the company with a buy rating. They give the biopharma a $7 price target. It also represents a potential 329% upside over the stock’s closing price on Thursday. Ladenburg analyst cites Artelo's focus on candidates targeting the endocannabinoid system. Artelo Biosciences is a biopharma company focused on developing treatments that improve patients’ lives. That includes developing new therapies. The company’s pipeline includes ART27.13, which is designed to treat cancer patients suffering from anorexia. This treatment is currently undergoing a Phase 1 clinical trial. seekingalpha.com investorplace.com
NASDAQ:ARTL
by AlenCiken
Medlab Ascending Channel(ASX:MDC) Medlab Clinical Ltd is an Australian, publicly listed biotechnology company that is finding new ways to address the biggest challenges of our time including the growing burden of cancer, suboptimal pain management as well as enhancing drug delivery with nanotechnology. Bullish Outlook: - Ascending Channel - Internal Uptrend - Bounce off RSI 50.00 - MACD crossing Bullish - Testing Daily Resistance - Positive Product Announcement Looking to see if price will break upper band of Ascending Channel and test former Resistance levels which align with TB Fib Extension Targets (1.), or will price consolidate for a short time before it breaks Daily Resistance after retesting Internal Uptrend Trendline (2.) Bearish Outlook: If Internal Uptrend Fails then a return to Daily Resistance and Lower band of Ascending Channel is likely, If it is to fail then there are 2 levels of former Support to watch (3.) "DISCLAIMER: NO ADVICE. The information presented here is general in nature and is for education purposes only. Nothing should be considered to be advice. You should consult with an appropriate professional for specific advice tailored to your situation."
ASX:MDCLong
by Trader_Johnni
Why $ANCN Anchiano Therapeutics Is Surging Today?Why $ANCN Anchiano Therapeutics Is Surging Today? Thanks to some news in December in the biopharma space, $ANCN stock is racing higher. So what was that news? And what else do you need to know? $ANCN Anchiano Therapeutics is captivating investors thanks to its Definitive Merger Agreement with Chemomab news in december. The proposed merger will create a public company focused on advancing Chemomab’s lead product, CM-101, a first in class anti-CCL24 antibody into advanced clinical development for fibrosis-related diseases with significant unmet medical need Concurrent PIPE financing to be used to fund clinical trials for CM-101 in fibrotic indications, focusing on two rare diseases and backed by leading healthcare-focused investors OrbiMed and Peter Thiel. Concurrent with the merger, Chemomab seeks to complete a PIPE financing to advance CM-101 into Phase 2 clinical trials in rare fibrotic indications, as well as to further develop Chemomab’s earlier-stage pipeline. We intend to hold a special meeting of Anchiano’s shareholders in the first quarter of 2021 to vote on this merger." finance.yahoo.com
A
by AlenCiken
$KALV Reports Positive Results for KVD900 Phase 2$KALV KalVista Pharmaceuticals Reports Positive Results for KVD900 Phase 2 Demonstrating Statistically and Clinically Significant Responses Across All Endpoints as an Oral On-Demand Treatment for HAE Attacks – Oral KVD900 Primary Endpoint Shows Only 15% Use of Rescue Medication in Patients with Hereditary Angioedema (HAE) – – KVD900 Generally Safe and Well-Tolerated – There were no serious adverse events reported in the trial and no patients withdrew due to adverse events. finance.yahoo.com
NASDAQ:KALV
by AlenCiken
1
$ZOM Increases Bought Deal Offering of Common Shares to $173.5 MZomedica Corp. Increases Previously Announced Bought Deal Offering of Common Shares to $173.5 Million. today announced that, due to demand, the underwriter has agreed to increase the size of the previously announced public offering and purchase on a firm commitment basis 91,315,790 common shares of Zomedica, at a price to the public of $1.90 per share, less underwriting discounts and commissions. The closing of the offering is expected to occur on or about February 11, 2021, subject to satisfaction of customary closing conditions. finance.yahoo.com
AMEX:ZOM
by AlenCiken
2
$OTLK Secures Funding to Support ONS-5010 / LYTENAVA™Outlook Therapeutics Increases Previously Announced Bought Deal Offering of Common Stock to $35.0 Million announced today that, due to demand, the underwriter has agreed to increase the size of the previously announced public offering and purchase on a firm commitment basis 35,000,000 shares of common stock of Outlook Therapeutics, at a price to the public of $1.00 per share, less underwriting discounts and commissions. finance.yahoo.com Outlook Therapeutics Announces Closing of $35.0 Million Bought Deal finance.yahoo.com Outlook Therapeutics’ Recent Financing Secures Funding to Support ONS-5010 / LYTENAVA™ (bevacizumab-vikg) Through Planned BLA Submission The combined net proceeds from these stock offerings are expected to provide sufficient capital to fund operations through the expected filing of the Biologics License Application (BLA) for ONS-5010 for wet age-related macular degeneration (wet AMD), which is planned for the end of calendar 2021 . “Not only have we secured enough capital to significantly extend our cash runway through important upcoming milestones in 2021, but we have provided ourselves with more time to unlock the greatest value and potential for ONS-5010, the company, and our stockholders. We believe we are now in an improved position that will allow us to both maximize the value of this asset and to provide an FDA-approved ophthalmic formulation of bevacizumab to patients .” Extensive market research indicates that ONS-5010, if approved, will be a significant therapy in the retinal anti-VEGF market, currently estimated to be in excess of $13 billion worldwide. Clinical Progress of ONS-5010 On Track - Therapeutics expects to report pivotal safety and efficacy data in the third calendar quarter of 2021. finance.yahoo.com
NASDAQ:OTLK
by AlenCiken
$OCGN Skyrockets On $23M Capital Raise Issued On 46% PremiumOcugen Inc. Announces $23 Million Registered Direct Offering of Common Stock Priced at a Premium to Market. today announced that it has entered into definitive agreements with healthcare-focused institutional investors for the sale of an aggregate of 3,000,000 shares of its common stock at a purchase price of $7.65 per share in a registered direct offering. The offering is expected to close on or about February 10, 2021, subject to the satisfaction of customary closing conditions. The gross proceeds of the offering are expected to be approximately $23 million, prior to deducting placement agent’s fees and other offering expenses payable by Ocugen. Ocugen intends to use the net proceeds from the offering for general corporate purposes, capital expenditures, working capital and general and administrative expenses. finance.yahoo.com
NASDAQ:OCGN
by AlenCiken
7
OCGN and Bharat Biote Announce Execution of Definitive AgreementOcugen and Bharat Biotech Announce Execution of Definitive Agreement for the Commercialization of COVAXIN™ in the US Market. Definitive Agreement provides details of the previously announced intent to co-develop COVAXIN™ for the US market. Ocugen and Bharat Biotech to share US commercialization profits. Ocugen to receive initial supply of COVAXIN™ doses from Bharat Biotech upon authorization from US regulatory authorities while it ramps up manufacturing in the US. COVAXIN™ received EUA (Emergency Use Authorization) in India in January and is currently in a fully enrolled Phase 3 clinical trial involving 25,800 patients. COVAXIN™ (whole-virion inactivated COVID-19 vaccine candidate) effectively neutralizes UK variant of SARS-Cov-2 reducing the possibility of mutant virus escape. today announced they have entered into a definitive agreement to co-develop, supply, and commercialize Bharat Biotech’s COVAXIN™ , an advanced stage whole-virion inactivated COVID-19 vaccine candidate, for the United States market. Ocugen will have US rights to the vaccine candidate and will be responsible for clinical development , regulatory approval (including EUA) and commercialization for the US market . B harat Biotech will supply initial dose s to be used in the US upon Ocugen’s receipt of an EUA. In addition, Bharat Biotech will support the technology transfer for manufacturing in the US . In consideration for the exclusive license to the US market, Ocugen will share the profits from the sale of COVAXIN™ in the US market with Bharat Biotech, with Ocugen retaining 45% of the profits. In preparation for the development of COVAXIN™ in the US, Ocugen’s Vaccine Scientific Advisory Board and Ocugen management have initiated discussions with the U.S. Food & Drug Administration (FDA) and the Biomedical Advanced Research and Development Authority (BARDA) to develop a regulatory path to EUA and, eventually, biologics license application (BLA) approval in the US market for COVAXIN™. Ocugen is also in active discussions with manufacturers in the US to produce a significant number of doses of COVAXIN™ to support its US immunization program. H.C. Wainwright analyst Swayampakula Ramakanth raised his rating on Ocugen's stock on Thursday from neutral to buy and placed a $4.50 price forecast on its shares. Ramakanth cheered Ocugen's recent deal with India-based vaccine developer Bharat Biotech to potentially bring Covaxin, a COVID-19 vaccine candidate, to the U.S. market. Ramakanth posits that Covaxin could induce broader immunity and better protection against new coronavirus strains than the COVID-19 vaccines that have received emergency use authorization in the U.S. He also highlighted Covaxin's potential logistical advantages, due to its less onerous temperature storage requirements. Roth Capital analyst Zegbeh Jallah, meanwhile, believes Ocugen's share price could rise to as high as $8. Jallah applauded the structure of the deal, which gave Ocugen a 45% share of the potential profits from Covaxin's U.S. sales without requiring it to make an upfront payment to Bharat Biotech . Jallah's price target represents potential gains for investors of roughly 52% from Ocugen's closing price on Friday. Much of Ocugen's future growth prospects now rest on its ability to obtain emergency use authorization for Covaxin in the U.S . Thus, investors should brace for volatility in Ocugen's stock price as it advances toward clinical trials.
NASDAQ:OCGN
by AlenCiken
4
Vistagen (VTGN): Long-term Game-changer* This is not financial advice. This is my non-expert opinion. * Vistagen ( NASDAQ:VTGN ) is a clinical stage biopharmaceutical company with long-term potential. I believe it's technology is similarly game-changing the way I believe NanoFlu for Novavax is (www.novavax.com) ( ). It could have positive outcomes for the world. I hope that their tech comes to fruition. Their pipeline includes Neuroactive nasal sprays that don't involve benzodiazepine and its associated side effects. I hope they succeed because it could change the way patients with anxiety or depression-related disorders are treated. Vistagen: www.vistagen.com Pipeline: www.vistagen.com PH94B Neuroactive Nasal Spray is their most advanced candidate, which is currently in Stage 3 clinical trials. I encourage anyone who wants to do their own research. This animated demonstration was very informative for me www.youtube.com Keep an eye out for this company.
NASDAQ:VTGNLong
by traderman001
23andMe to Merge with Virgin Group's VG Acquisition Corp. SPAC23andMe to Merge with Virgin Group's VG Acquisition Corp. to Become Publicly-Traded Company Set to Revolutionize Personalized Healthcare and Therapeutic Development through Human Genetics. - 23andMe is a leading consumer genetics and research company that offers a personalized health and wellness experience, and has built a premier genetic database to unlock insights leading to the rapid discovery of promising new targets for drug development - Transaction will provide the capital to fund additional investment in key growth initiatives across 23andMe's consumer health and therapeutics businesses - The transaction will value the outstanding shares of capital stock of 23andMe at an aggregate enterprise value of approximately $3.5 billion - 23andMe CEO and Co-Founder Anne Wojcicki and Virgin Group's Sir Richard Branson are each investing $25 million into the $250 million PIPE and are joined by leading institutional investors including Fidelity Management & Research Company LLC, Altimeter Capital, Casdin Capital and Foresite Capital - The pro forma cash balance of the combined company will exceed $900 million at closing Completion of the transaction, estimated in the second calendar quarter of 2021. 23andMe is the only consumer genetic testing company with multiple FDA clearances for over-the-counter health and carrier status reports. 23andMe's existing equity holders will roll 100% of their equity into the combined company. Assuming no public shareholders of VG Acquisition Corp. exercise their redemption rights, 23andMe will be capitalized with up to $984 million in cash to fund operations and support new and existing growth initiatives. finance.yahoo.com
V
by AlenCiken
Sympathy playSympathy play Anavex stock gained after favorable data from Cassava Sciences in Alzheimer’s! With a rise yesterday, Cassava Sciences extended its gains after announcement of favorable data from an open-label study in Alzheimer’s disease! The shares have been on a bullish mode for the last several days, reaching an all-time high, on encouraging data for its differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders such as Alzheimer's disease, Parkinson's disease, Rett syndrome, and other central nervous system diseases.
NASDAQ:AVXL
by AlenCiken
2
“Strong Buy” Penny Stock With Over 200% Upside on the Horizon“Strong Buy” Penny Stock With Over 200% Upside on the Horizon a biotechnology company with a focus on the treatment of glioblastomas, a class of aggressive tumors that attack the braid and spinal cord. These cancers, while rare, are almost always terminal, and CNS is working a new therapy designed to more effectively cross the blood-brain barrier to attack glioblastoma. Berubicin, CNS’s flagship drug candidate, is an anthracycline, a potent class of chemotherapy drugs derived from the Streptomyces bacteria strains, and used in the treatment of a wide variety of cancers. Berubicin is the first drug in this class to show promise against glioblastoma cancers. The drug candidate has completed its Phase 1 clinical trial, in which 44% of patients showed a clinical response. This number included one patient who showed a ‘Durable Complete Response,’ defined as a demonstrated lack of detectable cancer. Following the success of the Phase 1 study, CNS applied for, and received, FDA approval of its Investigational New Drug application. This gives the company the go-ahead to conduct a Phase 2 study on adult patients, an important next step in the development of the drug. CNS plans to start the mid-stage trial in 1Q21. Based on the potential of the company’s asset in glioblastoma, and with its share price at $2.22, several analysts believe that now is the time to buy. Among the bulls is Brookline’s 5-star analyst Kumaraguru Raja who takes a bullish stance on CNSP shares. Berubicin is the first anthracycline to cross the blood-brain barrier in adults and access brain tumors… Berubicin has promising clinical data in a Phase 1 trial in recurrent glioblastoma (rGBM) and has Orphan drug designation for treatment of malignant gliomas from the FDA. We model approval of Berubicin for treatment of recurrent glioblastoma in 2025 based on the Phase 2 data with 55% probability of success for approval. We model peak sales of $533 million in 2032,” Raja opined. “CNS pipeline also includes WP1244 (novel DNA binding agent) that is 500x more potent than daunorubicin in inhibiting tumor cell proliferation is expected to enter the clinic in 2021… In vivo testing in orthotopic models of brain cancer showed high uptake of WP1244 by brain and subsequent antitumor activity,” the analyst added. finance.yahoo.com
NASDAQ:CNSP
by AlenCiken
2